AI-Designed Drug Shows Promise in Treating Incurable Lung Disease
An AI-generated drug developed by Insilico Medicine has demonstrated significant potential in treating idiopathic pulmonary fibrosis (IPF), a previously incurable lung disease. The drug, rentosertib, improved lung function in a 12-week clinical trial involving 71 patients, targeting proteins linked to lung scarring.
This breakthrough marks the first successful intermediate clinical trial for an AI-designed drug, offering new hope for IPF patients. Insilico Medicine plans to expand trials and leverage the data to refine its AI-driven drug discovery platform, underscoring the transformative impact of artificial intelligence on healthcare innovation.